|
FR2705686B1
(fr)
*
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
|
ES2224113T5
(es)
*
|
1994-02-16 |
2009-05-01 |
The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Polipeptido antigenico asociado al melanoma, epitopos del mismo y vacunas contra melanoma.
|
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
|
DE69633565T3
(de)
*
|
1995-06-15 |
2013-01-17 |
Crucell Holland B.V. |
Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
|
|
US6265212B1
(en)
|
1995-06-15 |
2001-07-24 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
|
US20020068049A1
(en)
*
|
1998-09-10 |
2002-06-06 |
Henderson Daniel R. |
Tissue specific adenoviral vectors
|
|
US20040156861A1
(en)
*
|
1996-07-11 |
2004-08-12 |
Figdor Carl Gustav |
Melanoma associated peptide analogues and vaccines against melanoma
|
|
US5877011A
(en)
*
|
1996-11-20 |
1999-03-02 |
Genzyme Corporation |
Chimeric adenoviral vectors
|
|
US5849561A
(en)
*
|
1997-05-22 |
1998-12-15 |
Cornell Research Foundation, Inc. |
Method for the production of non-group C adenoviral vectors
|
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
|
US20040204381A1
(en)
*
|
1997-11-12 |
2004-10-14 |
Moskal Joseph R |
Detection and treatment of glyco-enzyme-related disease
|
|
US6670188B1
(en)
*
|
1998-04-24 |
2003-12-30 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
|
AU4070499A
(en)
*
|
1998-04-30 |
1999-11-16 |
Cornell Research Foundation Inc. |
Adenoviral vectors with tandem fiber proteins
|
|
US6413776B1
(en)
|
1998-06-12 |
2002-07-02 |
Galapagos Geonomics N.V. |
High throughput screening of gene function using adenoviral libraries for functional genomics applications
|
|
US20030017138A1
(en)
*
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
|
US20040043489A1
(en)
*
|
1998-07-08 |
2004-03-04 |
Menzo Havenga |
Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
|
|
IL141403A0
(en)
*
|
1998-08-28 |
2002-03-10 |
Univ Duke |
Deleted adenoviruses and methods of making and administering the same
|
|
US6929946B1
(en)
*
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
|
US6224566B1
(en)
|
1999-05-04 |
2001-05-01 |
Cardiodyne, Inc. |
Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium
|
|
ATE519854T1
(de)
*
|
1999-05-17 |
2011-08-15 |
Crucell Holland Bv |
Rekombinantes adenovirus auf basis von serotyp 48 (ad48).
|
|
WO2003104467A1
(en)
*
|
2002-04-25 |
2003-12-18 |
Crucell Holland B.V. |
Means and methods for the production of adenovirus vectors
|
|
US20050232900A1
(en)
*
|
1999-05-18 |
2005-10-20 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
|
US6913922B1
(en)
*
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
|
US6492169B1
(en)
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
|
EP1157999A1
(en)
*
|
2000-05-24 |
2001-11-28 |
Introgene B.V. |
Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
|
|
EP1322774A2
(en)
*
|
2000-09-20 |
2003-07-02 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for dendritic cells
|
|
DE60138403D1
(de)
*
|
2000-09-26 |
2009-05-28 |
Crucell Holland Bv |
Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
|
|
CA2439185A1
(en)
*
|
2001-02-23 |
2002-09-06 |
Novartis Ag |
Vector constructs
|
|
US20040253210A1
(en)
*
|
2001-08-30 |
2004-12-16 |
Marjorie Robert-Guroff |
Adenovirus type7 vectors
|
|
US7375206B2
(en)
*
|
2002-02-22 |
2008-05-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Brother of the regulator of imprinted sites (BORIS)
|
|
US20040106194A1
(en)
*
|
2002-08-22 |
2004-06-03 |
Bett Andrew J. |
Methods for propagating adenovirus and virus produced thereby
|
|
US20040166091A1
(en)
*
|
2003-02-24 |
2004-08-26 |
Genvec, Inc. |
Materials and methods for treating disorders of the ear
|
|
ES2391975T3
(es)
*
|
2003-07-25 |
2012-12-03 |
Genvec, Inc. |
Vacunas a base de vector adenovírico
|
|
JP2007511507A
(ja)
*
|
2003-11-14 |
2007-05-10 |
ジェンベク、インコーポレイティッド |
癌を処置するための治療レジメン
|
|
AU2004293474B2
(en)
*
|
2003-11-24 |
2010-12-23 |
Canji, Inc. |
Reduction of dermal scarring
|
|
CN1922308A
(zh)
*
|
2004-02-23 |
2007-02-28 |
克鲁塞尔荷兰公司 |
病毒纯化方法
|
|
WO2005110492A2
(en)
|
2004-04-12 |
2005-11-24 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method of using adenoviral vectors to induce an immune response
|
|
EP1769077A2
(en)
*
|
2004-07-20 |
2007-04-04 |
The University Of Warwick |
Adenovirus vector and method to manipulate the adenovirus genome
|
|
WO2006039045A2
(en)
*
|
2004-09-01 |
2006-04-13 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adenoviral vectors able to transduce apcs, potential use in immune response generation
|
|
WO2006086357A2
(en)
*
|
2005-02-10 |
2006-08-17 |
Merck & Co., Inc. |
Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
|
|
ATE412737T1
(de)
*
|
2005-04-11 |
2008-11-15 |
Crucell Holland Bv |
Virusreinigung mit ultrafiltration
|
|
US8765146B2
(en)
*
|
2005-08-31 |
2014-07-01 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
|
US8450055B2
(en)
*
|
2005-08-31 |
2013-05-28 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
|
US9651543B2
(en)
|
2005-08-31 |
2017-05-16 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
|
WO2007059461A2
(en)
*
|
2005-11-10 |
2007-05-24 |
Genvec, Inc. |
Adenoviral vector-based foot-and-mouth disease vaccine
|
|
WO2008086386A2
(en)
*
|
2007-01-09 |
2008-07-17 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
|
US20090202492A1
(en)
*
|
2008-01-25 |
2009-08-13 |
University Of South Florida |
Adenovirus vaccine utilizing ikk as adjuvant
|
|
WO2009149252A1
(en)
*
|
2008-06-04 |
2009-12-10 |
Cornell University |
Vaccines for prevention and treatment of addiction
|
|
EA019928B1
(ru)
|
2008-11-03 |
2014-07-30 |
Круселл Холланд Б.В. |
Способ получения аденовирусных векторов
|
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
|
WO2011045381A1
(en)
|
2009-10-15 |
2011-04-21 |
Crucell Holland B.V. |
Process for adenovirus purification from high cell density cultures
|
|
MX2012004222A
(es)
|
2009-10-15 |
2012-06-08 |
Crucell Holland Bv |
Metodo para purificacion de particulas de adenovirus.
|
|
WO2011047316A1
(en)
|
2009-10-16 |
2011-04-21 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Nucleic acid sequences encoding expandable hiv mosaic proteins
|
|
WO2011057254A2
(en)
|
2009-11-09 |
2011-05-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Simian adenoviral vector-based vaccines
|
|
WO2011057248A2
(en)
|
2009-11-09 |
2011-05-12 |
Genvec, Inc. |
Simian adenovirus and methods of use
|
|
PL2536829T3
(pl)
|
2010-02-15 |
2016-09-30 |
|
Sposób wytwarzania wektorów adenowirusowych Ad26
|
|
WO2011116189A1
(en)
|
2010-03-17 |
2011-09-22 |
Cornell University |
Disrupted adenovirus-based vaccine against drugs of abuse
|
|
EP2550359B1
(en)
|
2010-03-23 |
2017-08-09 |
Intrexon Corporation |
Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
|
|
WO2012021730A2
(en)
|
2010-08-11 |
2012-02-16 |
Genvec, Inc. |
Respiratory syncytial virus (rsv) vaccine
|
|
CA2808556A1
(en)
|
2010-09-20 |
2012-03-29 |
Crucell Holland B.V. |
Therapeutic vaccination against active tuberculosis
|
|
BR112013004582A2
(pt)
|
2010-09-27 |
2016-09-06 |
Crucell Holland Bv |
método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
|
|
WO2012083297A2
(en)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Adenoviral vectors with modified hexon regions
|
|
WO2012088041A1
(en)
|
2010-12-20 |
2012-06-28 |
Genvec, Inc. |
Adenoviral vector-based dengue fever vaccine
|
|
EP2681327B1
(en)
|
2011-03-04 |
2018-11-21 |
Intrexon Corporation |
Vectors conditionally expressing protein
|
|
WO2012162428A1
(en)
|
2011-05-23 |
2012-11-29 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Prime-boost vaccination for viral infection
|
|
CA2851251C
(en)
|
2011-10-05 |
2023-09-12 |
Genvec, Inc. |
Simian (gorilla) adenovirus or adenoviral vectors and methods of use
|
|
BR112014008167B1
(pt)
|
2011-10-05 |
2022-05-24 |
Genvec Inc |
Adenovírus ou vetor adenoviral e composição os compreendendo
|
|
WO2013052859A2
(en)
|
2011-10-05 |
2013-04-11 |
Genvec, Inc. |
Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
|
|
CA2850627C
(en)
|
2011-10-05 |
2024-05-21 |
Genvec, Inc. |
Affenadenovirus (gorilla) or adenoviral vectors and methods of use
|
|
WO2013074501A1
(en)
|
2011-11-14 |
2013-05-23 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
|
US20150157700A1
(en)
|
2012-02-02 |
2015-06-11 |
GanVec, Inc. |
Adenoviral vector-based malaria vaccine
|
|
KR102044051B1
(ko)
|
2012-03-12 |
2019-11-12 |
얀센 백신스 앤드 프리벤션 비.브이. |
터미널 말단이 변경된 재조합 아데노바이러스의 배치
|
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
US9125870B2
(en)
|
2012-03-22 |
2015-09-08 |
Crucell Holland B.V. |
Vaccine against RSV
|
|
JP5845376B2
(ja)
|
2012-03-22 |
2016-01-20 |
クルセル ホランド ベー ヴェー |
Ｒｓｖに対するワクチン
|
|
US10004811B2
(en)
|
2012-04-13 |
2018-06-26 |
Cornell University |
Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
|
|
EP2855669B1
(en)
|
2012-05-29 |
2018-10-10 |
GenVec, Inc. |
Modified serotype 28 adenoviral vectors
|
|
EP2855511B1
(en)
|
2012-05-29 |
2019-07-24 |
GenVec, Inc. |
Herpes simplex virus vaccine
|
|
EP4421177A3
(en)
|
2013-03-13 |
2024-12-18 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Prefusion rsv f proteins and their use
|
|
PT2988780T
(pt)
|
2013-04-25 |
2019-03-25 |
Janssen Vaccines & Prevention Bv |
Polipeptídeos f de pré-fusão do rsv solúveis estabilizados
|
|
CN105408348B
(zh)
|
2013-06-17 |
2021-07-06 |
扬森疫苗与预防公司 |
稳定化的可溶性融合前rsv f多肽
|
|
CN111514314A
(zh)
|
2013-09-19 |
2020-08-11 |
扬森疫苗与预防公司 |
改进的腺病毒配制品
|
|
US10400015B2
(en)
|
2014-09-04 |
2019-09-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant HIV-1 envelope proteins and their use
|
|
EA201790551A1
(ru)
|
2014-09-07 |
2017-07-31 |
Селекта Байосайенсиз, Инк. |
Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору
|
|
TWI710635B
(zh)
|
2014-10-09 |
2020-11-21 |
美商珍維克公司 |
編碼人類無調同源物-1(hath1)之腺病毒載體
|
|
EP3421046A1
(en)
|
2014-11-04 |
2019-01-02 |
Janssen Vaccines & Prevention B.V. |
Therapeutic hpv16 vaccines
|
|
US10420834B2
(en)
|
2014-12-24 |
2019-09-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant metapneumovirus F proteins and their use
|
|
EP3247388B1
(en)
|
2015-01-20 |
2025-09-10 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof
|
|
US10301377B2
(en)
|
2015-02-24 |
2019-05-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
|
EP3271729B1
(en)
|
2015-03-18 |
2020-09-23 |
Janssen Vaccines & Prevention B.V. |
Assays for recombinant expression systems
|
|
AU2016249798B2
(en)
|
2015-04-14 |
2022-05-26 |
Janssen Vaccines And Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
|
CN107847580B
(zh)
|
2015-07-07 |
2022-08-12 |
扬森疫苗与预防公司 |
针对rsv的疫苗
|
|
AU2016289496B2
(en)
|
2015-07-07 |
2021-02-04 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F polypeptides
|
|
HK1252967A1
(zh)
|
2015-08-20 |
2019-06-06 |
Janssen Vaccines & Prevention B.V. |
治疗性hpv18疫苗
|
|
EA036412B1
(ru)
|
2015-10-06 |
2020-11-09 |
Янссен Вэксинс Энд Превеншн Б.В. |
Способ обеспечения защиты аденовируса от разрушения, вызванного взаимодействием с пластиком, и применение 2-гидроксипропил--циклодекстрина для защиты аденовируса
|
|
WO2017139392A1
(en)
|
2016-02-08 |
2017-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant hiv-1 envelope proteins and their use
|
|
EP3426291A1
(en)
|
2016-03-09 |
2019-01-16 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Recombinant hiv-1 envelope proteins and their use
|
|
MX2018012094A
(es)
|
2016-04-05 |
2019-01-10 |
Janssen Vaccines & Prevention Bv |
Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
|
|
AU2017248018A1
(en)
|
2016-04-05 |
2018-09-27 |
Janssen Vaccines & Prevention B.V. |
Vaccine against RSV
|
|
EP3452087A1
(en)
|
2016-05-02 |
2019-03-13 |
Janssen Vaccines & Prevention B.V. |
Therapeutic hpv vaccine combinations
|
|
BR112018072865A2
(pt)
|
2016-05-12 |
2019-04-30 |
Janssen Vaccines & Prevention B.V. |
promotor bidirecional potente e equilibrado
|
|
SG11201810078PA
(en)
|
2016-05-30 |
2018-12-28 |
Janssen Vaccines & Prevention Bv |
Stabilized pre-fusion rsv f proteins
|
|
US11001858B2
(en)
|
2016-06-20 |
2021-05-11 |
Janssen Vaccines & Prevention B.V. |
Potent and balanced bidirectional promoter
|
|
US10744196B2
(en)
|
2016-07-14 |
2020-08-18 |
Janssen Vaccines & Prevention B.V. |
HPV vaccines
|
|
CA3038968A1
(en)
|
2016-09-30 |
2018-04-05 |
Genvec, Inc. |
Adenovectors for delivery of therapeutic genetic material into t cells
|
|
EP4070815A1
(en)
|
2016-10-03 |
2022-10-12 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Hiv-1 env fusion peptide immunogens and their use
|
|
WO2018081318A1
(en)
|
2016-10-25 |
2018-05-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion coronavirus spike proteins and their use
|
|
WO2018109220A2
(en)
|
2016-12-16 |
2018-06-21 |
Institute For Research In Biomedicine |
Novel recombinant prefusion rsv f proteins and uses thereof
|
|
JP2020506890A
(ja)
|
2017-01-07 |
2020-03-05 |
セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． |
合成ナノキャリアにカップリングした免疫抑制剤のパターン化された投与
|
|
JP6721797B2
(ja)
|
2017-02-09 |
2020-07-15 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
異種遺伝子発現のための強力で短いプロモーター
|
|
WO2018176031A1
(en)
|
2017-03-24 |
2018-09-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Glycan-masked engineered outer domains of hiv-1 gp120 and their use
|
|
CN110506060B
(zh)
|
2017-03-30 |
2024-05-07 |
昆士兰大学 |
嵌合分子及其用途
|
|
CA3061278A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
|
WO2019040994A1
(en)
|
2017-09-01 |
2019-03-07 |
The Australian National University |
IMMUNOREGULATOR MOLECULES AND USES THEREOF
|
|
AU2018333566A1
(en)
|
2017-09-15 |
2020-02-27 |
Janssen Vaccines & Prevention B.V. |
Method for the safe induction of immunity against RSV
|
|
WO2019075360A1
(en)
|
2017-10-13 |
2019-04-18 |
Selecta Biosciences, Inc. |
METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES
|
|
EP3697440A1
(en)
|
2017-10-16 |
2020-08-26 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Recombinant hiv-1 envelope proteins and their use
|
|
WO2019086450A1
(en)
|
2017-10-31 |
2019-05-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
|
MX421606B
(es)
|
2017-10-31 |
2025-03-14 |
Janssen Vaccines & Prevention Bv |
Vectores adenovirales y usos de estos
|
|
SG11202003399TA
(en)
|
2017-10-31 |
2020-05-28 |
Janssen Vaccines & Prevention Bv |
Adenovirus and uses thereof
|
|
MX2020004488A
(es)
|
2017-10-31 |
2020-08-13 |
Janssen Vaccines & Prevention Bv |
Adenovirus y usos de estos.
|
|
PL3743106T3
(pl)
|
2018-01-23 |
2022-11-14 |
Janssen Vaccines & Prevention B.V. |
Szczepionki przeciwko wirusowi grypy i ich zastosowanie
|
|
JP2021515037A
(ja)
|
2018-02-26 |
2021-06-17 |
アントルクス，インコーポレーテッド |
寛容原性リポソーム及びその使用方法
|
|
IL277128B2
(en)
|
2018-03-06 |
2025-11-01 |
Precigen Inc |
Hepatitis b vaccines and uses of the same
|
|
SG11202008539YA
(en)
|
2018-03-06 |
2020-10-29 |
Precigen Inc |
Human papillomavirus vaccines and uses of the same
|
|
WO2020086483A1
(en)
|
2018-10-22 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant gp120 protein with v1-loop deletion
|
|
PE20211469A1
(es)
|
2018-11-13 |
2021-08-05 |
Janssen Vaccines And Prevention B V |
Proteinas f de prefusion del vrs estabilizadas
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
AU2020263900B2
(en)
|
2019-04-25 |
2026-04-16 |
Janssen Vaccines & Prevention B.V. |
Recombinant influenza antigens
|
|
CA3138525A1
(en)
|
2019-04-28 |
2020-11-05 |
Selecta Biosciences, Inc. |
Methods for treatment of subjects with preexisting immunity to viral transfer vectors
|
|
KR20220008875A
(ko)
|
2019-05-15 |
2022-01-21 |
얀센 백신스 앤드 프리벤션 비.브이. |
계절성 인플루엔자 백신과 아데노바이러스 기반 호흡기 세포융합 바이러스 백신의 공동투여
|
|
US20220193219A1
(en)
|
2019-05-15 |
2022-06-23 |
Janssen Vaccines & Prevention B.V. |
Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
|
|
CA3141863A1
(en)
|
2019-05-28 |
2020-12-03 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuated anti-viral transfer vector immune response
|
|
JP7865873B2
(ja)
|
2019-09-05 |
2026-05-26 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
インフルエンザウイルスワクチン及びその使用
|
|
CA3156471A1
(en)
|
2019-10-03 |
2021-04-08 |
Janssen Vaccines & Prevention B.V. |
Adenovirus vectors and uses thereof
|
|
US12680122B2
(en)
|
2019-10-08 |
2026-07-14 |
Trustees Of Boston College |
Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
|
|
EP4061405A1
(en)
|
2019-11-18 |
2022-09-28 |
Janssen Biotech, Inc. |
Vaccines based on mutant calr and jak2 and their uses
|
|
CN114981298B
(zh)
|
2019-12-12 |
2024-08-20 |
听治疗有限责任公司 |
用于预防和治疗听力损失的组合物和方法
|
|
CN115515627A
(zh)
|
2020-02-11 |
2022-12-23 |
美国政府(由卫生和人类服务部的部长所代表) |
SARS-CoV-2疫苗
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
JP2023517011A
(ja)
|
2020-03-05 |
2023-04-21 |
ネオティーエックス セラピューティクス リミテッド |
免疫細胞を用いて癌を治療するための方法および組成物
|
|
US11213482B1
(en)
|
2020-03-05 |
2022-01-04 |
University of Pittsburgh—Of the Commonwealth System of Higher Educat |
SARS-CoV-2 subunit vaccine and microneedle array delivery system
|
|
US11773391B2
(en)
|
2020-04-01 |
2023-10-03 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
|
|
WO2021209897A1
(en)
|
2020-04-13 |
2021-10-21 |
Janssen Biotech, Inc. |
Psma and steap1 vaccines and their uses
|
|
US12679870B2
(en)
|
2020-04-29 |
2026-07-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant human metapneumovirus F proteins and their use
|
|
WO2022009049A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
EP4175664A2
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
WO2022009051A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
A method for determining responsiveness to prostate cancer treatment
|
|
WO2022035860A2
(en)
|
2020-08-10 |
2022-02-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Replication-competent adenovirus type 4-hiv env vaccines and their use
|
|
US20240228549A1
(en)
|
2021-04-29 |
2024-07-11 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Prefusion-stabilized lassa virus glycoprotein complex and its use
|
|
EP4380613A1
(en)
|
2021-08-03 |
2024-06-12 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
|
|
US20230141563A1
(en)
|
2021-10-12 |
2023-05-11 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
|
WO2023091696A1
(en)
|
2021-11-19 |
2023-05-25 |
Christiana Care Gene Editing Institute, Inc. |
Adenovirus delivery system for cancer treatment
|
|
US20230357437A1
(en)
|
2022-03-09 |
2023-11-09 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
|
WO2023192835A1
(en)
|
2022-03-27 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Base-covered hiv-1 envelope ectodomains and their use
|
|
WO2023196898A1
(en)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Beta globin mimetic peptides and their use
|
|
EP4338727A1
(en)
|
2022-09-14 |
2024-03-20 |
Roquette Freres |
Adenovirus formulations
|
|
WO2024233783A1
(en)
|
2023-05-09 |
2024-11-14 |
Cornell University |
Expression cassette coding for vascular endothelial growth factor
|
|
WO2024249626A1
(en)
|
2023-05-30 |
2024-12-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Hiv-1 envelope triple tandem trimers and their use
|
|
WO2025158316A1
(en)
|
2024-01-26 |
2025-07-31 |
Janssen Biotech, Inc. |
Ovarian neoantigens and use thereof
|
|
WO2026030724A1
(en)
|
2024-08-01 |
2026-02-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Sars-cov-2 vaccine
|